- Home
- HEQ vs PRQR Comparison
HEQ vs PRQR Comparison
Compare HEQ & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- PRQR
- Stock Information
- Founded
- HEQ 2011
- PRQR 2012
- Country
- HEQ United States
- PRQR Netherlands
- Employees
- HEQ N/A
- PRQR N/A
- Industry
- HEQ Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- HEQ Finance
- PRQR Health Care
- Exchange
- HEQ Nasdaq
- PRQR Nasdaq
- Market Cap
- HEQ 130.2M
- PRQR 153.5M
- IPO Year
- HEQ N/A
- PRQR 2014
- Fundamental
- Price
- HEQ $10.98
- PRQR $4.49
- Analyst Decision
- HEQ
- PRQR Strong Buy
- Analyst Count
- HEQ 0
- PRQR 4
- Target Price
- HEQ N/A
- PRQR $3.38
- AVG Volume (30 Days)
- HEQ 43.1K
- PRQR 3.1M
- Earning Date
- HEQ 01-01-0001
- PRQR 11-05-2024
- Dividend Yield
- HEQ 9.78%
- PRQR N/A
- EPS Growth
- HEQ N/A
- PRQR N/A
- EPS
- HEQ N/A
- PRQR N/A
- Revenue
- HEQ N/A
- PRQR $16,902,389.00
- Revenue This Year
- HEQ N/A
- PRQR $305.55
- Revenue Next Year
- HEQ N/A
- PRQR N/A
- P/E Ratio
- HEQ N/A
- PRQR N/A
- Revenue Growth
- HEQ N/A
- PRQR 290.57
- 52 Week Low
- HEQ $9.08
- PRQR $1.11
- 52 Week High
- HEQ $11.84
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- HEQ 58.88
- PRQR 91.58
- Support Level
- HEQ $10.95
- PRQR $1.83
- Resistance Level
- HEQ $11.03
- PRQR $2.06
- Average True Range (ATR)
- HEQ 0.08
- PRQR 0.35
- MACD
- HEQ 0.00
- PRQR 0.25
- Stochastic Oscillator
- HEQ 78.26
- PRQR 95.49
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.